US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.62

+0.99512.96%

Post-market: 34.620.00000.00%19:30 EDT

Volume:31.48K

Turnover:1.09M

Market Cap:111.48M

PE:- -

High:34.68

Open:33.80

Low:33.71

Close:33.62

52wk High:36.84

52wk Low:25.00

Shares:3.22M

Float Shares:3.22M

Volume Ratio:0.39

T/O Rate:0.98%

Dividend:0.39

Dividend Rate:1.13%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

How Can Domestic Innovative Drugs Truly Go Global for the Long Haul?

Hong Kong Stock Concept Tracking: Third-Quarter Earnings Season Begins! AI and Innovative Drugs in Focus, How Should Investors Position for the Q3 Earnings Rally? (With Concept Stocks)

Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth

Simply Wall St.

Jinghua Pharmaceutical's Jidesheng Snake Medicine Tablet Gets Clinical Trial Approval for New Herpes Zoster Indication

Wolwo Bio-Pharmaceutical's Subsidiary Wins Clinical Trial Approval for Human Umbilical Cord Mesenchymal Stem Cell Type II Injection

Sichuan Biokin Gets NMPA Approval for Clinical Trial of Yizekang Combined with Radiotherapy in Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

Simply Wall St.

11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data

Simply Wall St.

Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Moderna Inc. Stock Advances 14.2%, Outperforms Peers

Vertex Pharmaceuticals to present data on Alyftrek at NACFC

Vertex Says Interim Alyftrek Study Data Show Some CF Children Ages 2-5 Regain Pancreatic Function

Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors

Retension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening

Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong

Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued

Simply Wall St.

Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants

Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000

Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IBBQ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.62,"timestamp":1791576000000,"preClose":33.6249,"halted":0,"volume":31484,"hourTrading":{"tag":"盘后","latestPrice":34.62,"preClose":34.62,"latestTime":"19:30 EDT","volume":37,"amount":1289.62,"timestamp":1791588605827,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.029594140056922128,"floatShares":3220001,"shares":3220001,"eps":0,"marketStatus":"Market Closed","change":0.9951,"latestTime":"10-09 16:00:00 EDT","open":33.8,"high":34.68,"low":33.7079,"amount":1085852.840908,"amplitude":0.02891,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":33.6249,"sharesOutstanding":2520001,"nav":33.62265,"aum":111665382.5,"dividendRate":0.011265,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.62,"preClose":34.62,"latestTime":"19:30 EDT","volume":37,"amount":1289.62,"timestamp":1791588605827,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.39329730648058625,"impliedVol":0.14,"impliedVolPercentile":0.6255},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":3220001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.39329730648058625,"shares":3220001,"dividePrice":0.39,"high":34.68,"amplitude":0.02891,"preClose":33.6249,"low":33.7079,"week52Low":25,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.62,"eps":0,"divideRate":0.011265,"volume":31484,"delay":0,"ttmEps":0,"open":33.8,"prevYearClose":28.3962,"prevWeekClose":34.37,"prevMonthClose":35.14,"prevQuarterClose":35.14,"fiveDayClose":34.37,"twentyDayClose":34.472,"sixtyDayClose":32.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165202895","title":"How Can Domestic Innovative Drugs Truly Go Global for the Long Haul?","url":"https://stock-news.laohu8.com/highlight/detail?id=1165202895","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165202895?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:31","pubTimestamp":1791761477,"startTime":"0","endTime":"0","summary":"Since the start of this year, the globalization of domestically developed innovative drugs has continued to advance, with multiple overseas licensing deals being finalized. Meanwhile, the industry is...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","IBBQ","BK1574","BK1161","MEDX","06978","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166516380","title":"Hong Kong Stock Concept Tracking: Third-Quarter Earnings Season Begins! AI and Innovative Drugs in Focus, How Should Investors Position for the Q3 Earnings Rally? (With Concept Stocks)","url":"https://stock-news.laohu8.com/highlight/detail?id=1166516380","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166516380?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:10","pubTimestamp":1791760243,"startTime":"0","endTime":"0","summary":"The third-quarter earnings disclosure window has officially opened, with listed companies beginning to release their results and many issuing advance earnings forecasts, some reporting net profit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","QTOC","AGIX","KCAI","BK4585","MEDX","AIPO","06978","LNGR","VTHR","VXUS","ARTY","BK1161","CHAT","159992","BK4588","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674481743","title":"Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2674481743","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674481743?lang=en_us&edition=fundamental","pubTime":"2026-10-11 19:28","pubTimestamp":1791718112,"startTime":"0","endTime":"0","summary":"Amgen has delivered a powerful run in recent years, and the question now is whether the current share price lines up with the cash flows that underpin the business. With the stock trading around recent highs, investors are asking how much of Amgen's future cash generation is already reflected in today's valuation.\n\nAmgen has returned 133.2% over the past 5 years, which puts real pressure on the numbers to show that the cash it can generate justifies that kind of long haul performance.\nThe...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-stock-could-be-39-undervalued-following-kras-mark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-stock-could-be-39-undervalued-following-kras-mark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B4R5TH58.HKD","BBH","PBE","BK4581","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","LU1571399168.USD","SPHQ","IBB","AMGN","BK4566","IBBQ","SG9999001440.SGD","LU2242646821.SGD","BK4534","BK4599","DCF","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","BK4588","IE0009355771.USD","LU2242652126.USD","BIB","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU0320765992.SGD","LU2112291526.USD","BK4533","LU1983299246.USD","LU0889565916.HKD","TBXU","IE00BJT1NW94.SGD","LU0109394709.USD","BK4585","PJP","LU2468319806.SGD","LU1023059063.AUD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185040470","title":"Jinghua Pharmaceutical's Jidesheng Snake Medicine Tablet Gets Clinical Trial Approval for New Herpes Zoster Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1185040470","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185040470?lang=en_us&edition=fundamental","pubTime":"2026-10-11 17:08","pubTimestamp":1791709690,"startTime":"0","endTime":"0","summary":"Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that the company recently received a Drug Clinical Trial Approval Notice (acceptance number: CXZL2600062; notice number: 2026LP03037)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSYK","BK0102","MDTX","002349","BMED","IBBQ","BK0239","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127340518","title":"Wolwo Bio-Pharmaceutical's Subsidiary Wins Clinical Trial Approval for Human Umbilical Cord Mesenchymal Stem Cell Type II Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1127340518","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127340518?lang=en_us&edition=fundamental","pubTime":"2026-10-11 17:04","pubTimestamp":1791709453,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) has announced that its indirectly controlled subsidiary, Zhejiang Wolwo Stem Cell Technology Co., Ltd. (hereinafter referred to as \"Zhejiang...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","MDTX","BK0028","BK0239","PSYK","300357","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113952133","title":"Sichuan Biokin Gets NMPA Approval for Clinical Trial of Yizekang Combined with Radiotherapy in Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1113952133","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113952133?lang=en_us&edition=fundamental","pubTime":"2026-10-11 16:26","pubTimestamp":1791707173,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) announced that the company recently received the official Drug Clinical Trial Approval Notice issued by the National Medical Products Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BMED","IBBJ","MDTX","91194","688506","BK0239","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674815517","title":"Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2674815517","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674815517?lang=en_us&edition=fundamental","pubTime":"2026-10-11 07:25","pubTimestamp":1791674706,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi, backed by a US$1b upfront payment.\nAll of this is landing while Regeneron Pharmaceuticals trades at US$746.54, with the share price up over the past quarter but down over the year to date. The 1 year total shareholder return of 32.9% indicates that momentum may be building again as investors...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0058720904.USD","IBB","LU0053666078.USD","LU1917777945.USD","LU0114720955.EUR","LU2023250504.SGD","LU0823434583.USD","BK4588","SNYNF","LU2362541273.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU2468319806.SGD","LU2362540622.SGD","IBBQ","LU1974910355.USD","LU0823416689.USD","TBXU","LU0889565916.HKD","LU2106854487.HKD","BK4585","LU2237438978.USD","LU2362541513.USD","BK4007","LU0289739699.SGD","LU2324357040.USD","BBH","REGN","LU0882574055.USD","LU2089984988.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889959","title":"11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889959","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674889959?lang=en_us&edition=fundamental","pubTime":"2026-10-10 15:30","pubTimestamp":1791617441,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) just put fresh clinical data for ALYFTREK in front of cystic fibrosis specialists at the North American Cystic Fibrosis Conference, highlighting early pancreatic function recovery in some very young children.\nVertex Pharmaceuticals’ recent ALYFTREK data arrives while the share price has climbed 12.82% year to date and the 1-year total shareholder return of 25.08% points to solid momentum, with a 5.09% 90-day share price return suggesting that investors are...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/11-undervalued-vertex-pharmaceuticals-vrtx-following-new-aly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/11-undervalued-vertex-pharmaceuticals-vrtx-following-new-aly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1778281490.HKD","BK4585","IE00BFTCPJ56.SGD","LU0234570918.USD","LU1585245621.USD","IDNA","LU0757428866.USD","IBB","LU2462157665.USD","LU1559883803.SGD","BIB","IBBQ","IE00B19Z9Z06.USD","VERX","LU0061475181.USD","BK4532","IE00BZ9MQY76.HKD","LU0256863811.USD","BBH","LU0889565916.HKD","LU1069344957.HKD","LU2236285917.USD","LU1674673691.USD","LU1093756168.USD","TBXU","LU1093756325.SGD","LU0058720904.USD","LU0566484027.USD","LU1674673428.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","BK4023","IE00B894F039.SGD","LU2362541513.USD","LU0109394709.USD","IE0002270589.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","LU2362541273.HKD","LU2417539215.USD","GNMX","IE00B19Z9P08.USD","VRTX","BK4588","PBE","LU0823416689.USD","BK4567","LU2456880835.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861455","title":"Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861455","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861455?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:34","pubTimestamp":1791578040,"startTime":"0","endTime":"0","summary":"DJ Amgen Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  advanced 1.82% to $414.87 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.59% to 7,811.54 and the Dow Jones Industrial Average  rising 0.83% to 51,654.95.Amgen Inc. closed 7.19% short of its 52-week high of $447.03, which the company reached on August 25th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson  rose 1.93% to $261.44, Pfizer Inc.  rose 1.65% to $28.28, and AbbVie Inc.  rose 1.49% to $276.47.Trading volume  remained 824,175 below its 50-day average volume of 2.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 9, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","PJP","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4581","IBBQ","BK4534","IE0002141913.USD","PBE","LU0109394709.USD","BIB","BBH","LU2089984988.USD","IBB","LU1061106388.HKD","IE00BFTCPJ56.SGD","04332","IE00B2B36J28.USD","BK4588","LU0320765992.SGD","LU1571399168.USD","LU2468319806.SGD","IE0009355771.USD","SG9999001440.SGD","LU2242646821.SGD","BK4599","LU0122379950.USD","LU0868494617.USD","LU0289739699.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","BK4533","BK4585","LU2112291526.USD","LU2242652126.USD","LU1983299246.USD","AMGN","LU1023059063.AUD","TBXU","LU0889565916.HKD","BK4139","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674614538","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2674614538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674614538?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:34","pubTimestamp":1791578040,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  advanced 2.77% to $151.17 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.59% to 7,811.54 and the Dow Jones Industrial Average  rising 0.83% to 51,654.95.This was the stock's third consecutive day of gains.Gilead Sciences Inc. closed 3.89% short of its 52-week high of $157.29, which the company reached on February 11th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  rose 1.93% to $261.44, Pfizer Inc.  rose 1.65% to $28.28, and Abbott Laboratories  rose 1.13% to $99.60.Trading volume  remained 643,432 below its 50-day average volume of 6.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 9, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0114720955.EUR","IBBQ","IE00B7SZLL34.SGD","LU1674673691.USD","LU0109394709.USD","IE00B3T34201.USD","TMED","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0859254822.USD","LU1585245621.USD","BIB","LU0234570918.USD","LU0882574055.USD","BBH","LU0965509283.SGD","SG9999015978.USD","LU0965509101.SGD","LU2089984988.USD","IBB","LU1061106388.HKD","SG9999015952.SGD","BK4550","LU0058720904.USD","LU2087621335.USD","IE0002270589.USD","LU0861579265.USD","LU1934455277.USD","LU1934455863.HKD","LU0965508806.USD","SG9999015986.USD","BK4588","LU1839511570.USD","LU0320765992.SGD","LU1571399168.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU2468319806.SGD","MEDI","LU0965509010.AUD","LU1674673428.USD","LU0122379950.USD","BK4583","LU1066053197.SGD","LU1037948897.HKD","LU2324357040.USD","LU0289739699.SGD","LU1057294990.SGD","LU2357627491.SGD","LU1430594728.SGD","LU1066051498.USD","IE00BSNM7G36.USD","BK4568","BK4532","BMED","BK4585","BK4578","LU2112291526.USD","LU1778281490.HKD","SG9999015945.SGD","LU1023059063.AUD","TBXU","LU0823416689.USD","LU0889565916.HKD","BK4139","IE00BKVL7J92.USD","LU1934455194.USD","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861788","title":"Moderna Inc. Stock Advances 14.2%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861788","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861788?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:32","pubTimestamp":1791577920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 14.2% to $225.00 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.6% to 27,366.17 and the Dow Jones Industrial Average rising 0.8% to 51,654.95.This was the stock's third consecutive day of gains.Moderna Inc. hit a new 52-week high, surpassing its previous peak of $212.22, which the company achieved on October 6th.The stock outperformed some of its peers, as Johnson & Johnson rose 1.9% to $261.44, Pfizer Inc. rose 1.7% to $28.28, and Gilead Sciences Inc. rose 2.77% to $151.17.Trading volume totaled 28.7 million, compared to the 50-day average of 21.5 million.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","IE00B3T34201.USD","LU1934455863.HKD","LU1674673691.USD","BMED","LGHT","BK4139","LU1023059063.AUD","MRNA","MRNX","LU0965508806.USD","MEDI","BK4551","LU0965509010.AUD","LU2468319806.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","LU0965509101.SGD","SG9999015952.SGD","LU2087621335.USD","LU1839511570.USD","BK4501","LU0882574055.USD","IE00B19Z3B42.SGD","MRNY","TMED","IE0002270589.USD","LU1057294990.SGD","LU1571399168.USD","GILD","LU1778281490.HKD","BK4548","LU1066051498.USD","IDNA","WDNA","LU1934455277.USD","LU0234570918.USD","SG9999015945.SGD","BK4533","IE00B19Z3581.USD","LU1934455194.USD","GNOM","BK4532","BBH","LU2357627491.SGD","IBBQ","LU0965509283.SGD","IBB","TBXU","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866511","title":"Vertex Pharmaceuticals to present data on Alyftrek at NACFC","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866511","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866511?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:20","pubTimestamp":1791566419,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) announced new interim data from the ALYFTREK 2 to 5 years old open-label extension study, highlighting recovery of ex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-to-present-data-on-alyftrek-at-nacfc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-to-present-data-on-alyftrek-at-nacfc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","IE00B4R5TH58.HKD","IBB","IE00B894F039.SGD","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU0109394709.USD","LU1778281490.HKD","SG9999013999.USD","LU0320765992.SGD","LU0432979614.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU0256863811.USD","LU1674673691.USD","LU2237438978.USD","TBXU","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","BK4023","LU0417517546.SGD","PBE","IE00BJT1NW94.SGD","LU2236285917.USD","IE0002270589.USD","LU2468319806.SGD","LU0061475181.USD","IE0009355771.USD","BK4139","BK4532","BIB","VRTX","LU2324357040.USD","SG9999001176.USD","IE00BFTCPJ56.SGD","LU0234570918.USD","IDNA","VERX","LU1585245621.USD","BBH","BK4588","LU1035775433.USD","GNMX","IE00B2B36J28.USD","LU0289739699.SGD","BK4567","SG9999001176.SGD","LU2089984988.USD","IBBQ","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674865094","title":"Vertex Says Interim Alyftrek Study Data Show Some CF Children Ages 2-5 Regain Pancreatic Function","url":"https://stock-news.laohu8.com/highlight/detail?id=2674865094","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674865094?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:15","pubTimestamp":1791566131,"startTime":"0","endTime":"0","summary":"Vertex says interim ALYFTREK study data show some CF children ages 2-5 regain pancreatic functionVertex flagged interim trial data on ALYFTREK showing some cystic fibrosis children ages 2 to 5 regaine","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL2tJqZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU0432979614.USD","LU2324357040.USD","IE00BJT1NW94.SGD","LU1674673428.USD","LU1778281490.HKD","IE00B19Z3581.USD","IE00BZ9MQY76.HKD","LU2237438978.USD","BIB","LU2362541513.USD","LU1069344957.HKD","SG9999013999.USD","LU0061475181.USD","IE00B19Z9Z06.USD","BK4585","LU0079474960.USD","LU1093756168.USD","LU2089984988.USD","LU2362541273.HKD","LU0889565916.HKD","BK4533","BBH","GNMX","LU0109394709.USD","LU2417539215.USD","LU0417517546.SGD","SG9999001176.SGD","IE0002141913.USD","IBBQ","VRTX","LU2468319806.SGD","IBB","TBXU","IDNA","BK4532","BK4139","IE00B894F039.SGD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0320765992.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","LU2462157665.USD","IE0002270589.USD","PBE","LU0234570918.USD","LU0058720904.USD","LU1674673691.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674902865","title":"Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2674902865","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674902865?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:30","pubTimestamp":1791563440,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA), Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. The Phase 1/2 study titled “A Phase 1/2 D...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-and-moderna-advance-cf-mrna-therapy-what-vx-522-trial-completion-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-and-moderna-advance-cf-mrna-therapy-what-vx-522-trial-completion-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823416689.USD","IE00B4R5TH58.HKD","IBB","IE00B894F039.SGD","LU2362540622.SGD","WDNA","ISBC","LU1778281490.HKD","LU0320765992.SGD","IE00B19Z9P08.USD","LU2237438978.USD","TBXU","LU0566484027.USD","MRNY","LU0889565916.HKD","IE00BJJMRZ35.SGD","MRNA","PBE","IE00BJT1NW94.SGD","BK4501","LU1069344957.HKD","IE0002270589.USD","BK4585","LU0061475181.USD","IE0009355771.USD","BK4139","BK4551","LU0757428866.USD","LGHT","BIB","VRTX","LU2324357040.USD","IE00BFTCPJ56.SGD","MRNX","IDNA","VERX","GNOM","LU1093756168.USD","LU1585245621.USD","BBH","BK4588","GNMX","IE00B2B36J28.USD","LU0289739699.SGD","BK4567","SG9999001176.SGD","LU2362541513.USD","IBBQ","BK4548","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144830990","title":"Retension Pharmaceuticals Debuts on US Stock Market, Shares Drop Over 10% After Opening","url":"https://stock-news.laohu8.com/highlight/detail?id=1144830990","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144830990?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:28","pubTimestamp":1791563294,"startTime":"0","endTime":"0","summary":"According to reports, on Friday, Retension Pharmaceuticals Inc (RTSN.US) listed on the US stock market. As of press time, the stock had fallen more than 10% to $10.77. The IPO price was $12.Retension...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","RTSN","MRNY","BBP","03069","IBBQ","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674328258","title":"Sino Biopharmaceutical Stock Falls 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2674328258","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674328258?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:33","pubTimestamp":1791534780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.41 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.8% to 24211.35.This was the stock's third consecutive day of losses.Sino Biopharmaceutical Ltd. closed 33% short of its 52-week high of HK$8.08, which the company reached Oct. 10.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 2.2% and Amgen Inc. remained unchanged.Trading volume totaled 72.7 million shares, compared to the 50-day average of 80.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1571399168.USD","LU2242652126.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU2089984988.USD","BK1521","BK4585","IE00BJJMRZ35.SGD","LU2242646821.SGD","IBBQ","BK1515","BK4581","AMGN","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00B4R5TH58.HKD","LU0289739699.SGD","BK1589","IE00BZ08YR35.GBP","LU0058720904.USD","PBE","LU0122379950.USD","BK4566","LU0889565916.HKD","LU2112291526.USD","BK4588","BK4599","BK4534","IE0002141913.USD","LU0868494617.USD","LU1057294990.SGD","LU0320765992.SGD","IBB","01177","PJP","IE00BZ08YT58.USD","LU0109394709.USD","IE00B2B36J28.USD","LU1061106388.HKD","BK1191","TBXU","LU1023059063.AUD","IE00BJT1NW94.SGD","BBH","LU1983299246.USD","BIB","IE0009355771.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674488039","title":"Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued","url":"https://stock-news.laohu8.com/highlight/detail?id=2674488039","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674488039?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:36","pubTimestamp":1791513400,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) is back in focus after fresh attention on its obesity drug candidate MariTide, now in late-stage Phase III testing, and new precision medicine partnerships that together are shaping sentiment toward the stock.\nThose headlines are landing on a stock that has already been rebuilding confidence. Amgen’s share price is up 12.12% over 90 days and 24.36% year to date, while its 1-year total shareholder return of 41.74% points to strong, dividend-backed momentum rather than a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-in-focus-as-maritide-buzz-tests-whether-the-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-in-focus-as-maritide-buzz-tests-whether-the-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0868494617.USD","LU1057294990.SGD","BK4588","BK4581","LU2112291526.USD","BK4139","IE00B2B36J28.USD","BK4599","IE00B4R5TH58.HKD","PJP","LU0109394709.USD","BIB","LU1061106388.HKD","BK4585","LU2089984988.USD","IE00BJT1NW94.SGD","TBXU","BK4566","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1571399168.USD","LU2242652126.USD","LU0889565916.HKD","AMGN","IBB","IE0002141913.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","BBH","BK4534","LU0289739699.SGD","LU2242646821.SGD","LU1023059063.AUD","LU0122379950.USD","LU0058720904.USD","PBE","IBBQ","SG9999001440.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674886821","title":"Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886821?lang=en_us&edition=fundamental","pubTime":"2026-10-09 07:38","pubTimestamp":1791502698,"startTime":"0","endTime":"0","summary":"An update from Vertex Resource Group Ltd. ( ($TSE:VTX) ) is now available. Vertex Resource Group Ltd., a North American environmental services firm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0417517546.SGD","LU1674673428.USD","SG9999001176.USD","TBXU","LU1778281490.HKD","PBE","LU2468319806.SGD","IE0002141913.USD","IE00B894F039.SGD","IE00B19Z3B42.SGD","IBB","VRTX","LU2462157665.USD","LU0058720904.USD","BK4585","BK4588","BBH","LU0757428866.USD","IE00B2B36J28.USD","LU2456880835.USD","LU1815336091.USD","IE0009355771.USD","LU1035775433.USD","SGXZ57979304.SGD","LU2362541273.HKD","LU0061475181.USD","LU1093756168.USD","BK4139","LU2089984988.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU1559883803.SGD","LU0566484027.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU2362541513.USD","IBBQ","LU2417539215.USD","IE00B4R5TH58.HKD","LU2237438978.USD","BK4567","SG9999013999.USD","BK4532","VERX","IE00BJT1NW94.SGD","BIB","IDNA","GNMX","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883067","title":"Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883067?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:30","pubTimestamp":1791498600,"startTime":"0","endTime":"0","summary":"SHERWOOD PARK, AB, Oct. 8, 2026 /CNW/ -- (TSXV: VTX) -- Vertex Resource Group Ltd. (\"Vertex\" or the \"Corporation\") announces its intention to enter into a subordinated credit arrangement with Factory ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU2417539215.USD","LU1093756325.SGD","LU1674673691.USD","LU2456880835.USD","PBE","91512","SG9999013999.USD","IE00BZ9MQY76.HKD","BK4588","BBH","LU0566484027.USD","IE0009355771.USD","TBXU","LU2462157665.USD","BIB","LU0109394709.USD","LU2362541273.HKD","BK4585","IE0002270589.USD","IE00BJT1NW94.SGD","LU0757428866.USD","LU1674673428.USD","BK4139","LU2362540622.SGD","IBB","LU2468319806.SGD","SGXZ57979304.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0079474960.USD","BK4567","LU1585245621.USD","LU0061475181.USD","IBBQ","LU0289739699.SGD","LU2237438978.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","BK4533","SG9999001176.USD","LU0432979614.USD","VRTX","91013","VERX","SG9999001176.SGD","GNMX","IDNA","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674009023","title":"Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674009023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674009023?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:31","pubTimestamp":1791477115,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen lines up a head-to-head diabetes trial that could reshape the GLP-1 la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-monthly-diabetes-shot-takes-aim-at-semaglutide-in-new-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-monthly-diabetes-shot-takes-aim-at-semaglutide-in-new-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","PJP","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4581","IBBQ","BK4534","IE0002141913.USD","PBE","LU0109394709.USD","BIB","BBH","LU2089984988.USD","IBB","LU1061106388.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4588","LU0320765992.SGD","LU1571399168.USD","LU2468319806.SGD","IE0009355771.USD","SG9999001440.SGD","LU2242646821.SGD","BK4599","LU0122379950.USD","LU0868494617.USD","LU0289739699.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","BK4533","BK4585","LU2112291526.USD","LU2242652126.USD","JDOC","LU1983299246.USD","AMGN","LU1023059063.AUD","TBXU","LU0889565916.HKD","BK4139","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}